SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Watson Pharmaceuticals
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Dan'l Leviton who wrote (72)3/29/1998 7:12:00 PM
From: Jacob Snyder  Read Replies (1) of 83
 
Re: Dilacor is easily company's most important product:

Dilacor is a calcium channel blocker, which is a class of blood pressure medications that is going out of favor. Basically, they are more expensive than the older classes of drugs. Worse than that, in spite of a huge research effort, no drug in this class has been shown to increase lifespan, or decrease mortality. A big advertising effort is propping up sales of these drugs, but a consensus conference has clearly stated that calcium channel blockers should not be first-line therapy.

When the market corrects, when the drug industry cycles out of favor, when Dilacor sales dissapoint, then WPI will be available at a PE of 14 again, and I'll buy it again. I'm prepared to be very patient. I spend most of my investing time watching and doing nothing, and this is my most profitable activity.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News